Use of 13-hode as a regulator of vascular biocompatibility and an inhibitor of cell hyperplasia
OwnerMichael R Buchanan, David Horrobininventors
Life of this patent
Estimating the term…
Abstract
This invention relates to the regulation of vascular endothelium biocompatibility and to the inhibition of vessel wall cell and other types of cell hyperplasia following vessel wall dysfunction and/or injury More particularly, the invention relates to the dietetic and pharmaceutical preparations of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) and its use in reducing or inhibiting vessel wall hyperplasia and restoring vessel wall biocompatibility.
Claims26
A method of reducing or inhibiting cell hyperplasia and restoring vessel wall biocompatibility in a mammal or human in need of such treatment comprising administering orally an amount of 13-hydroxyoctadeca-9Z, 11E-dienoic acid (13-HODE) effective to reduce or inhibit vessel wall thrombogenicity where the 13-HODE is administered as a pharmaceutical composition comprising 13-HODE and a carrier comprising either a mono- di- or triglyceride oil, or an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.
A method of correcting the inhibition of endogenous 13-HODE synthesis by omega-3 fatty acids by incorporating 13-HODE into formulations of omega-3 fatty acids.
The method of claim 10 or 11, wherein the omega-3 fatty acid is selected from the group consisting of EPA, DHA, a derivative of EPA and a derivative of DHA.
The method of claim 10 or 11, wherein the omega-3 fatty acid is selected from the group consisting of ethyl-EPA and ethyl-DHA.
A pharmaceutical composition for the oral administration of 13-HODE in which the 13-HODE is formulated with a carrier comprising either a mono-, di-, or triglyceride oil or an ester of a fatty acid containing 16-26 carbon atoms and one or more double bonds.
A pharmaceutical composition of 13-HODE comprising 13-HODE and omega-3 fatty acids.
The use of the pharmaceutical composition of claim 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 to treat:
- (a) cardiovascular or cerebrovascular disease
- (b) inflammatory or autoimmune disease
- (c) infection with bacteria, viruses, fungi, or protozoa,
- (d) respiratory disease
- (e) gastrointestinal disease
- (f) renal or urinary tract disease
- (g) skin disease
- (h) neurological or psychiatric disease
- (i) disease of the reproductive system
- (j) diabetes, syndrome A or any complication of diabetes
The use of the pharmaceutical compositions of 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 and 21 to treat a disease or condition associated with overactive protein kinases.
Dependencies are inferred from the claim text.